alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 76–92 of 92 studies with an author at Seoul National University (KR) (page 4 of 4) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 92 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review

✓ Peer-reviewed alzhub usefulness score 42 out of 100. European journal of medicinal chemistry 2019-03-08

Plant iridoids such as catalpol and its 10-O-trans-p-coumaroyl derivative, geniposide, harpagoside, and loganin, and seco-iridoids, oleuropein and its aglycone and oleocanthal have been found to exhibit significant neuroprotective effect and the property of slowing down the process of neurogedeneration in AD and PD. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Vascular and degenerative processes differentially affect regional interhemispheric connections in normal aging, mild cognitive impairment, and Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Stroke 2010-07-01

We found differential region-specific associations between degenerative and vascular processes and the structural integrity of the CC across the spectrum of cognitive ability. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The patient pathway for mild cognitive impairment due to Alzheimer’s disease in Asia: Current practices, barriers, and expert recommendations for optimization

✓ Peer-reviewed alzhub usefulness score 42 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-06-06

Forty-four physicians, primarily neurologists (n = 31; 70.5 %), were interviewed. 5 key findings →

Participants: 31 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Validity of the telephone interview for cognitive status (TICS) and modified TICS (TICSm) for mild cognitive imparment (MCI) and dementia screening

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Archives of gerontology and geriatrics 2010-05-14

This study aimed to validate the TICS and modified TICS (TICSm) in Korean elderly population and to compare MCI and dementia screening ability between TICS and TICSm. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The Validity and Reliability of the Mini-Mental State Examination-2 for Detecting Vascular Mild Cognitive Impairment and Vascular Dementia in a Korean Population

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Korean Medical Science 2025-01-01

The MMSE-2 demonstrated robust performance in differentiating participants across Clinical Dementia Rating (CDR) stages and CDR-Sum of Boxes scores. 5 key findings →

Participants: 66 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuroticism, conscientiousness, and in vivo Alzheimer pathologies measured by amyloid PET and MRI

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Psychiatry and clinical neurosciences 2020-02-23

The present findings suggest that amyloid-independent regional neurodegeneration might underlie relations of neuroticism and conscientiousness with AD. 4 key findings →

Participants: 397 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diagnostic accuracy of mini-mental status examination and revised hasegawa dementia scale for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Dementia and geriatric cognitive disorders 2005-03-22

To compare the diagnostic accuracies of the Revised Hasegawa Dementia Scale (HDS-R) and Mini-Mental Status Examination (MMSE) for Alzheimer's diseases (AD), we administered them simultaneously to 82 AD patients and 82 age- and sex-matched nondemented control subjects. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Both Targeted Mass Spectrometry and Flow Sorting Analysis Methods Detected the Decreased Serum Apolipoprotein E Level in Alzheimer's Disease Patients

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Molecular & Cellular Proteomics 2013-12-08

Apolipoprotein E (ApoE) polymorphism has been appreciated as a valuable predictor of Alzheimer disease (AD), and the associated ε4 allele has been recognized as an indicator of susceptibility to this disease. 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Long-Term Effects of Mobile-Based Metamemory Cognitive Training in Older Adults With Mild Cognitive Impairment: 15-Month Prospective Single-Arm Longitudinal Study

✓ Peer-reviewed alzhub usefulness score 34 out of 100. JMIR Aging 2025-12-05

=3.40; P=.04). Greater cognitive improvements were associated with younger age, higher functional status, and lower baseline cognitive function. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Resting state electroencephalography alpha activity predicts cognitive scores in rapid eye movement sleep behavior disorder

✓ Peer-reviewed alzhub usefulness score 32 out of 100. SLEEP Advances 2025-01-01

Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is characterized by the loss of atonia during REM sleep, causing dream-enacting behavior. 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

ICF Application and Assessment Tool Analysis for Dysphagia Evaluation in Patients with Dementia: A Scoping Review

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Journal of the Korean Dysphagia Society 2025-12-30

Instrumental assessments (Videofluoroscopic Swallowing Study [VFSS], Fiberoptic Endoscopic Evaluation of Swallowing [FEES]) and the Water Swallow Test were most frequently used.ICF mapping revealed that 96.7% of tools focused on body functions, while only approximately 20% addressed participation and environmental factors. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Korean version of mini mental status examination for dementia screening and its' short form

⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. Psychiatry investigation 2010-04-06

We developed a Korean version of Mini-Mental Status Examination (MMSE) optimized for screening dementia (MMSE-DS) and its' short form (SMMSE-DS). 4 key findings →

Participants: 1,555 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

GCH1 genetic variation as a prognostic factor in Parkinsons disease across populations

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-08-19

BackgroundPathogenic variants in GCH1 have been associated with Parkinsons disease (PD), but the clinical phenotype and longitudinal disease course of GCH1-associated PD remain incompletely characterized. 5 key findings →

Design: longitudinal study Participants: 22,825 Evidence: moderate

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed